Institute of Biopharmaceutical Technology, University of Applied Sciences Giessen-Friedberg, Giessen, Germany.
Adv Biochem Eng Biotechnol. 2010;123:143-62. doi: 10.1007/10_2009_25.
Cell based therapy promises the treatment of many diseases like diabetes mellitus, Parkinson disease or stroke. Microencapsulation of the cells protects them against host-vs-graft reactions and thus enables the usage of allogenic cell lines for the manufacturing of cell therapeutic implants. The production process of such implants consists mainly of the three steps expansion of the cells, encapsulation of the cells, and cultivation of the encapsulated cells in order to increase their vitality and thus quality. This chapter deals with the development of fixed-bed bioreactor-based cultivation procedures used in the first and third step of production. The bioreactor system for the expansion of the stem cell line (hMSC-TERT) is based on non-porous glass spheres, which support cell growth and harvesting with high yield and vitality. The cultivation process for the spherical cell based implants leads to an increase of vitality and additionally enables the application of a medium-based differentiation protocol.
基于细胞的疗法有望治疗多种疾病，如糖尿病、帕金森病或中风。细胞的微囊化保护它们免受宿主对移植物的反应，从而使同种异体细胞系能够用于制造细胞治疗性植入物。此类植入物的生产过程主要包括三个步骤：细胞的扩增、细胞的包封以及包封细胞的培养，以提高其活力，从而提高其质量。本章介绍了在生产的第一和第三步中使用的基于固定床生物反应器的培养程序的开发。用于扩增干细胞系（hMSC-TERT）的生物反应器系统基于无孔玻璃球，可支持细胞生长和收获，具有高产量和活力。基于球形细胞的植入物的培养过程可提高活力，并可应用基于培养基的分化方案。
